Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)

• Status: Recruiting
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: All

Summary

Preoperative anemia, bleeding and transfusions have been recognized as a "Deadly triad" in cardiac surgery associated with an increased morbidity,mortality, and costs related. Thus strategies to reduce unnecessary RBC transfusions and to optimize preoperative anemia must be developed .The study evaluate an individual blood conservation strategy based on patient blood management bundles in cardiac surgery patients: optimisation perioperative hemoglobin level by erythropoietin and ferric carboxymaltose (Ferinject) associated with the use of ScV02 to guide perioperative erythrocyte transfusion.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Montpellier
• Treatments: Epoetin Alfa; Ferric Compounds; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Scheduled Cardiac surgery for more than 24 hours

• High risk of perioperative transfusion defined by a TRUST Score ≥ 3

• Veno-Venous catheter in Superior vena cava territory

• Patient Affiliate or beneficiary of social security

• Collection on free, informed and written consent

Exclusion Criteria:

• EPO and FCM contraindication

• Patients already treated by EPO at the time of inclusion

• Non controlled Infectious endocarditis defined by ESC guidelines 2015

• Patients including in an other research

• Patients whose physical and/or psychological health is severely impaired and who, according to the investigator, may affect the participant's compliance with the study.

• Patients deprived from his rights (guardianship or tutelage measure)

• Patients who refuses to sign the consent

• pregnant or lactating woman